Chinese Academy of

Company snapshot

Chinese Academy of maintains 1328 tracked programs across Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease, Lung Cancer, Immune Thrombocytopenia, Stroke, Head and Neck Squamous Cell Carcinoma, Sepsis, Multiple Myeloma, Acute Ischemic Stroke. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, p

• 1328 active pipeline program(s) linked via ClinicalTrials.gov.
• 335 US patent(s) indexed to this assignee profile.
• 1328 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chinese Academy of. Not investment advice.

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 70

• Peer + 0 momentum

  Hospital Authority

  TA overlap score 60

• Peer + 0 momentum

  United Therapeutics Europe

  TA overlap score 50

• Peer + 0 momentum

  Universal Integrated

  TA overlap score 37.8

• Peer + 0 momentum

  Tvardi Therapeutics

  TA overlap score 31.2

• Peer + 0 momentum

  Chinese University of

  TA overlap score 28.4

• Peer + 0 momentum

  LIGAND PHARMACEUTICALS

  TA overlap score 26.8

• Peer + 0 momentum

  Samsung Bioepis

  TA overlap score 24.8

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  CASI Pharmaceuticals

  TA overlap score 24.4

Recent activity

Latest pipeline, patent, and corporate events for Chinese Academy of.

1. Jun 8, 2026 Clinical update

   IIT2025111 — Phase 2

2. Jun 8, 2026 Clinical update

   2026（225） — Phase 2

3. Jun 8, 2026 Clinical update

   [2025]372-001 — Phase 3

4. Jun 8, 2026 Clinical update

   NHL-014 — Phase 3

5. Jun 8, 2026 Clinical update

   DLY201619 — Phase 3

View all clinical trial activity →

• What is Chinese Academy of?

  Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. NovaPharmaNews links 1328 clinical program(s), 0 drug profile(s)

• Is Chinese Academy of publicly traded?

  Chinese Academy of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chinese Academy of develop or market?

  We link 711 drug profile(s) where Chinese Academy of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/china-sxt-pharmaceuticals#company-drugs.

• What are the latest developments for Chinese Academy of?

  In the last 12 months our linked public records show 1328 trial program update(s) and 18 US patent grant(s) tied to this profile.

• What therapeutic areas does Chinese Academy of focus on?

  Chinese Academy of focuses on Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19 based on our analysis of their pipeline programs and drug development activities.